Milbank LLP advised Apotea AB (publ) in connection with its initial public offering and Nasdaq Stockholm listing. The offering, which closed on December 10, 2024, priced at SEK 58 per share, resulting in total proceeds of SEK 1.9 billion (assuming the exercise of the overallotment option) and valuing Apotea at approximately SEK 6 billion.
Apotea is Sweden’s leading online pharmacy by market share with three million active customers. With the widest assortment on the market, low prices and quick deliveries, Apotea facilitates everyday life for its three million active customers.
The Milbank team was led by Capital Markets partner David Dixter and included associates Marina Carvalho Rodriguez and Lays Lima Dutra, as well as Tax partner Andrew Walker and associate Michael Rivkin, and Alternative Investments partner Catherine Leef Martin.
